会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER
    • 大肠癌的诊断和预后
    • WO2007068985A2
    • 2007-06-21
    • PCT/GB2006050460
    • 2006-12-15
    • ELECTROPHORETICS LTDJOUBERT RICHARDPREFOT PETRABOEHM GITTEARNHOLD JUERGENHOEHLE CLAUDIANEUKUM ERHARDSCHAEFER JURGEN
    • JOUBERT RICHARDPREFOT PETRABOEHM GITTEARNHOLD JUERGENHOEHLE CLAUDIANEUKUM ERHARDSCHAEFER JURGEN
    • A61K38/17G01N33/57419
    • The invention relates to a method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being: transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Q15582); suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2); hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7); calponin-2 (SwissProt Acc. No. Q99439); heat shock protein HSP90-beta (SwissProt Acc. No. P08238); phosphoglycerate mutase 1 (SwissProt Acc. No. P18669); serpin C1 protein (SwissProt Acc. No. P01008); or haptoglobin precursor (SwissProt Acc. No. P00738); or a decreased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being serotransferrin (SwissProt Acc. No. P02787); 26S proteasome subunit p40.5 (Swiss Prot Acc. No. Q9UNM7); aldo-keto reductase family 1 member B10 (SwissProt Acc. No. O60218); fructosamine-3-kinase (SwissProt Acc. No. Q9H479); peripherin (SwissProt Acc. No. P41219); alpha-2-macroglobulin (SwissProt Acc. No. P01023); serpin C1 protein (SwissProt Acc. No. P01008); or apolipoprotein A IV (SwissProt Acc. No. P06727). The same proteins can be used for prognosis by detecting changes in their concentration in the course of treatment for colorectal cancer.
    • 本发明涉及一种诊断取自人受试者的有效身体组织的诊断样品中的结直肠癌的方法,其包括检测诊断样品中蛋白质浓度与对照,正常人样品, 蛋白质是:转化生长因子-β诱导的蛋白质IG-H3(SwissProt Acc.No.Q15582); SKP1同系物(亚型2)(SwissProt Acc.No.Q9Y2Z0-2)的G2等位基因抑制子; 假想蛋白质(URG4的一部分)(SwissProt Acc.No.Q9NWR7); calponin-2(SwissProt登录号Q99439); 热休克蛋白HSP90-β(SwissProt Acc.No.P08238); 磷酸甘油酸变位酶1(SwissProt Acc.No.P18669); 丝氨酸蛋白酶抑制剂C1蛋白(SwissProt Acc.No.P01008); 或触珠蛋白前体(SwissProt Acc.No.P00738); 或与正常人样品相比,诊断样品中蛋白质浓度降低,所述蛋白质是血清转铁蛋白(SwissProt Acc.No.P02787); 26S蛋白酶体亚基p40.5(Swiss Prot Acc.No.Q9UNM7); 醛酮还原酶家族1成员B10(SwissProt Acc.No.O60218); 果糖胺-3-激酶(SwissProt Acc.No.Q9H479); 外周蛋白(SwissProt Acc.No.P41219); α-2-巨球蛋白(SwissProt Acc.No.P01023); 丝氨酸蛋白酶抑制剂C1蛋白(SwissProt Acc.No.P01008); 或载脂蛋白A IV(SwissProt Acc.No.P06727)。 通过检测结肠直肠癌治疗过程中其浓度的变化,可以将相同的蛋白质用于预后。